Clinical trials: COPD Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD.
- Trial name
- SUSPIRE-1 (NCT06533553)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 23 sites in United States
- Volunteers
- 30 people
- Sponsor
- Areteia Therapeutics
Pulmonary Disease, Chronic Obstructive
Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)
Study to evaluate the pharmacokinetics of tiotropium following 14 days of administration (18µg once per day) in elderly COPD patients.
- Trial name
- NCT02172326
- Testing
- Tiotropium inhalation capsules for oral inhalation
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
This trial in healthy subjects will assess PUR118's effect on attenuating ozone induced airway inflammation. This trial will establish the tolerability of PUR118 in healthy normal volunteers.
- Trial name
- NCT01690949
- Testing
- PUR118
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- OBERON (NCT05166889)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Argentina and 19 more
- Volunteers
- 1,132 people
- Sponsor
- AstraZeneca
COPD
Drug-drug Interaction Study of CHF5993 With Cimetidine
The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993 (pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of the organic cation transport in the kidneys), by…
- Trial name
- NCT02287272
- Testing
- CHF 5993 pMDI, Cimetidine plus CHF5993 pMDI
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol.
- Trial name
- EOS (NCT00313209)
- Testing
- Roflumilast
- Where
- 134 sites in Austria, Belgium and 8 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease
To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
- Trial name
- NCT02238132
- Testing
- ATROVENT® inhalets
- Volunteers
- 374 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care
This is a prospective, observational, non-drug interventional, non-randomized study to compare the rate of moderate-severe COPD exacerbations in patients of all Chronic Obstructive Pulmonary Disease (COPD) severities with and…
- Trial name
- ACCESS (NCT01516528)
- Testing
- Spirometry
- Where
- 233 sites in Belgium, France and 4 more
- Volunteers
- 3,500 people
- Sponsor
- GlaxoSmithKline
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.
- Trial name
- CODEX (NCT00489853)
- Testing
- budesonide/formoterol Turbuhaler 320/9µg, formoterol Turbuhaler 9µg
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
COPD
Pharmacokinetics and Safety Study of PT010 in Healthy Subjects
This is a single-center, Phase I, healthy adult subject study with a randomized, double blind, three period, three-treatment, cross-over design.
- Trial name
- NCT02189304
- Testing
- PT010, PT009, Symbicort Turbohaler
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.
- Trial name
- NCT00782535
- Testing
- CHF 4226 pMDI
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation…
- Trial name
- NCT06748079
- Testing
- TQC3721 inhalation powder, TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
This is a multi-center, randomized, double-blind, parallel group, chronic dosing, active-controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007).
- Trial name
- NCT01970878
- Testing
- GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005)
- Where
- 125 sites in United States, Australia and 1 more
- Volunteers
- 892 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Cardiac Safety of Indacaterol
This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
- Trial name
- NCT01263808
- Testing
- Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg
- Where
- United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in the treatment of cough in patients with stable obstructive pulmonary disease
- Trial name
- NCT03159091
- Testing
- Rengalin
- Where
- 18 sites in Russia
- Volunteers
- 238 people
- Sponsor
- Materia Medica Holding
Pulmonary Disease, Chronic Obstructive
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431287
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 240 sites in United States, Austria and 22 more
- Volunteers
- 2,539 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug delivery characteristics comparable to the…
- Trial name
- NCT01540708
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.